2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 403

Peripheral Blood Biomarkers Of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Abstract Number: 534

Peripheral Blood Gene Expression Profiling Of Psoriatic Arthritis Patient
Abstract Number: 1776

Peripheral Blood Memory B Cell Numbers Predict Clinical Response Following Rituximab Treatment Of Adult and Childhood Myositis
Abstract Number: 2906

Peripheral Blood Mononuclear Cells Co-Cultured With Autologous Skin Fibroblasts Up-Regulate IL-17A and Play Anti-Fibrotic Effects In Systemic Sclerosis
Abstract Number: 694

Peripheral Bone Marrow-Derived Endothelial Progenitor Cells and N-Terminal Probrain Natriuretic Peptide in Scleroderma Mexican Patients With and Without Diastolic Dysfunction: A Preliminary Report
Abstract Number: 1238

Persistence At 12 Months With Denosumab (Prolia^®) In Postmenopausal Women With Osteoporosis: Interim Results From a Prospective Observational Study
Abstract Number: 2324

Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient
Abstract Number: 1424

Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Abstract Number: 1800

Persistent Fatty Lesions In The Vertebrae In Ankylosing Spondylitis Favor Subsequent New Syndesmophytes: Imaging Results Of a Phase III, Randomized, Placebo-Controlled Study
Abstract Number: 2340

Persistent Use Of Biologic Therapies At Lower Than Recommended Dosing Among Rheumatoid Arthritis Patients Enrolled In The US Medicare Program
Abstract Number: 2903

Perturbed Response To Experimental Renal Injury In a TGFβ Dependent Mouse Model Of Scleroderma
Abstract Number: 457

Pharmacodynamic Effect Of Intravenous Golimumab By Messenger Ribonucleic Acid Expression Profiling
Abstract Number: 2551

Pharmacodynamics and Predictive Biomarkers In Patients Treated With Atacicept: Data From The APRIL-SLE Trial
Abstract Number: 2374

Pharmacodynamics Of a Novel Jak1 Selective Inhibitor In Rat Arthritis and Anemia Models and In Healthy Human Subjects
Abstract Number: 2361

Pharmacokinetic and Pharmacodynamic Characterization Of a Dissociated Agonist Of Glucocorticoid Receptor, Following Multiple Dose Administration In Healthy Japanese Adult Subjects

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].